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Zehra Kevser Timur, Secil Akyildiz Demir and Volkan Seyrantepe*
Izmir Institute of Technology, Molecular Biology and Genetics, Izmir, Turkey
Lysosomal serine carboxypeptidase Cathepsin A (CTSA) is a multifunctional enzyme with
distinct protective and catalytic function. CTSA present in the lysosomal multienzyme
complex to facilitate the correct lysosomal routing, stability and activation of with
beta–galactosidase and alpha-neuraminidase. Beside CTSA has role in inactivation
of bioactive peptides including bradykinin, substances P, oxytocin, angiotensin I and
endothelin-I by cleavage of 1 or 2 amino acid(s) from C-terminal ends. In this study, we
aimed to elucidate the regulatory role of CTSA on bioactive peptides in knock-in mice
model of CTSAS190A. We investigated the level of bradykinin, substances P, oxytocin,
angiotensin I and endothelin-I in the kidney, liver, lung, brain and serum from CTSAS190A
mouse model at 3- and 6-months of age. Our results suggest CTSA selectively
contributes to processing of bioactive peptides in different tissues from CTSAS190A mice
compared to age matched WT mice.
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INTRODUCTION
Lysosomal CathepsinA (CTSA), belonging to serine proteases family, is a multifunctional
glycoprotein with three distinctive hydrolytic activities for deamidase, esterase and
carboxypeptidase. It also makes a complex with the two glycosidases, β-galactosidase (β-gal)
and α–neuraminidase (Neu1) to protect them against proteolytic degradation in lysosome
(reviewed in Bonten et al., 2014). CTSA is necessary for oligomerization and catalytic activation of
Neu1 (Itoh et al., 2000). Molecular defect of the CTSA cause autosomal recessively inherited rare
lysosomal storage disease; galactosialidosis (D’azzo et al., 1982; Caciotti et al., 2013).
CTSA is widely distributed but differentially expressed in human tissues with the highest
expression in the distal and collecting tubular cells of kidney, epithelial cells of lung, liver and large
neurons of brain (Satake et al., 1994; Sohma et al., 1999). In mice, the highest level expression of
CTSA is observed in kidney, brain, liver and placenta (Galjart et al., 1990). Secreted to the blood
plasma by platelets and lymphocytes, CTSA very likely plays an extralysosomal (cell membrane)
and/or extracellular regulatory role for a variety of bioactive peptide hydrolyzing them (Jackman
et al., 1990).
CTSA is a member of α/β hydrolase fold family and has significant sequence homology in a
conserved active side with two yeast enzymes, the KEX1 gene product and carboxypeptidase Y
and wheat serine carboxypeptidase suggested the involvement of CTSA in different proteolytic
functions in different cellular locations (Galjart et al., 1988; Hiraiwa, 1999). Several studies
have shown that in vitro CTSA hydrolyze short regulatory bioactive short peptides including
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bradykinin, substances P, oxytocin, angiotensin I and endothelin-
I (Jackman et al., 1992, 1993; Skidgel and Erdös, 1998). However,
the physiological functions of CTSA outside the lysosome have
not been explored fully. To elucidate this function, previously we
have generated a knock-in mice model of CTSAS190A by replacing
the nucleophile of the CTSA active site, Serine at 190 with
Alanine. While the mutant CTSA protein retained its ability to
form a complex with β-gal and Neu1, it has abolished enzymatic
activity. CTSAS190A knock-in mice with inactive CTSA had a
significantly induced level of bioactive short peptide endothelin-
I resulting increased arterial blood pressure (Seyrantepe et al.,
2008). In this study, we aimed to clarify significance of lysosomal
CTSA in the regulation of several endogenous bioactive peptides
including bradykinin, substances P, oxytocin, angiotensin I as
well as endothelin-I in different tissues from CTSAS190A mice
model at two different age groups.
MATERIALS AND METHODS
Animals
CTSAS190A knock-in mice model were previously generated by
Dr. Volkan Seyrantepe in Montreal, Canada and donated by Dr.
Alexey V. Pshezhetsky (Centre Hospitaliere Universitaire Sainte-
Justine, University of Montreal, Montreal, Quebec, Canada).
CTSAS190A knock-in male mice was used and breed with
C57/BL6 females for at least 10 generation to establish mice
colony. All mice were bred and maintained in the Turkish
Council on Animal Care (TCAC) accredited animal facility of
Izmir Institute of Technology according to the TCAC guidelines.
Mice were housed under constant room temperature and
humidity on a 12 h light:dark cycle with ad libitum access to
food and water. The animal care and the use in the experiments
were granted by the Animal Care and Use Committee of Ege
University, Izmir, Turkey.
Sample Preparation
3- and 6-months-old CTSAS190A and wild-type (WT) littermate
male mice were analyzed (n = 3). Blood samples were collected
in a centrifuge tube (stabilized with EDTA) after the cardiac
puncture under anesthesia. Blood was centrifuged at 4◦C; 1600 g
for 15 min and serum was stored at −80◦C. Kidney, liver, lung
and brain were taken, snap freezed with liquid nitrogen and kept
in−80◦C up to 30 days.
Peptide Isolation
For extraction of peptides, 350mg of kidney, 1 g of liver, 170mg
of lung and 360mg of brain from CTSAS190A and WT male
mice were homogenized in 5 ml/g cold lysis buffer (10 mM
Tris, pH 7.4) using homogenizer (IKA T10 Basic Ultra-Turra-
fold). After centrifugation of homogenate (1600 g for 15 min at
4◦C), Aprotinin (RK-APRO) was added to all samples including
serum at 1/10 (v/v) ratio. Peptides were purified with SEP-Pak
C18 column (Phoenix Strata) from homogenized tissues and
serum of mice. Eluted samples were first lyophilized (Labconco-
Freezone Lyophilizer) and then pellet were re-suspended with
ELISA 1-fold Assay Buffer.
ELISA Assays
Peptides from kidney, liver, lung, brain and serum were analyzed
using Enzyme Immuno Assay kit (Phoenix Pharmaceutical—
Bradykinin, Substances P, Oxytocin, Angiotensin I and
Endothelin-I) according to manufacturer’s instruction.
Statistical Analysis
Collected data correspond to means of 3 different animals with
same sex age and genotype was analyzed using one-way ANOVA.
Data were considered significant if P < 0.05.
RESULTS
In the concept of this study, we determined the level of five
different endogenous bioactive peptides (bradykinin, substances
P, oxytocin, angiotensin I and endothelin-I) in kidney, liver, lung,
brain and serum from CTSAS190A andWT male mice at 3- and 6-
months-old in order to reveal the importance of lysosomal CTSA
on the regulation of bioactive peptides in vivo.
Kidney
CTSAS190A male mice at the age of 3 months had elevated
levels of bradykinin (2.2-fold), oxytocin (2.3-fold), angiotensin-I
(1.2-fold) and endothelin-I (1.6-fold) compared to WT mice in
kidney. However, no differences were detected in the levels of
substances P in the same tissue from age matching CTSAS190A
and WT male mice (Figure 1). In 6 month old CTSAS190A
mice’s kidney, the level of bradykinin, oxytocin and angiotensin-I
were higher (1.3-fold, 1.2-fold and 1.5-fold, respectively) whereas
substances P and endothelin-I levels were similar to agematching
WT mice (Figure 1).
Liver
3 months old CTSAS190A male mice showed significant increase
in oxytocin level (5.8 -fold) in liver while other peptides were
similar to WT. However, CTSAS190A male mice at the age of 6
month, had higher levels of bradykinin (2.9 -fold) and substances
P (1.3-fold) in same tissue compared to WT (Figure 2). Lower
oxytocin level was detected in older CTSAS190A however it was
higher (1.4-fold) as compared to WT mice.
Lung
Bradykinin (1.5-fold), substances P (1.3-fold), oxytocin (1.6-fold)
and endothelin-I (1.4-fold) levels were significantly higher in the
lung tissue from 6 months old CTSAS190A male mice but not
in younger mice. No difference was detected in the levels of
Angiotensin I in the lung from 6 months old CTSAS190A and
WT male mice. Only oxytocin level in lung tissue from 3 months
old CTSAS190A male mice was higher (2.4-fold) compared toWT
male mice (Figure 3).
Brain
In the brain, the analysis of the bioactive peptides showed
that oxytocin (14.2-fold) and substances P (5.2-fold) level was
significantly higher in only 3 months old CTSAS190A mice
compared to WT mice. However, no accumulations of other
peptides were detected (Figure 4).
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FIGURE 1 | The levels of bradykinin, substance P, oxytocin, angiotensin I and endothelin-I in the kidney of 3-month-old (3M) and 6-month-old (6M)
CathAS190A mice and WT littermate mice. Data show mean± SE of measurements in three male mice. Significant levels of Student’s t-tests are shown below the
boxplots. The symbol “ ____ ” indicates significant levels of bradykinin, substance P, angiotensin I and endothelin I between 3- and 6-month-old CathAS190A mice
using the one-way ANOVA (*p < 0.05 and **p < 0.025).
FIGURE 2 | The levels of bradykinin, substance P, oxytocin, angiotensin I and endothelin-I in the liver of 3-month-old (3M) and 6-month-old (6M)
CathAS190A mice and WT littermate mice. Data show mean ± SE of measurements in three male mice. Significant levels of Student’s t-tests are shown below the
boxplots. The symbol “ ____ ” indicates significant level of oxytocin and angiotensin I between 3- and 6-month-old CathAS190A mice using the one-way ANOVA
(*p < 0.05 and **p < 0.025).
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FIGURE 3 | The levels of bradykinin, substance P, oxytocin, angiotensin I and endothelin-I in the lung of 3-month-old (3M) and 6-month-old (6M)
CathAS190A and WT littermate mice. Data show mean ± SE of measurements in three male mice. Significant levels of Student’s t-tests are shown below the
boxplots. The symbol “ ____ ” indicates significant levels of bradykinin, substance P and oxytocin between 3- and 6-month-old CathAS190A mice using the one-way
ANOVA (*p < 0.05 and **p < 0.025).
FIGURE 4 | The levels of bradykinin, substance P, oxytocin, angiotensin I and endothelin-I in the brain of 3-month-old (3M) and 6-month-old (6M)
CathAS190A and WT littermate mice. Data show mean ± SE of measurements in three male mice. Significant levels of Student’s t-tests are shown below the
boxplots. The symbol “ ____ ” indicates significant level of substance P and oxytocin between 3- and 6-month-old CathAS190A mice using the one-way ANOVA
(*p < 0.05 and **p < 0.025).
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Serum
We detected significantly higher level of bradykinin in serum
from 3 months old (2.4-fold) as well as 6 months old (1.2-fold)
CTSAS190A male mice compared to age-matched WT mice. The
level of oxytocin in serum of CTSAS190A mice was higher (4.1-
fold) in 3 months old but not in the older mice. On the other
hand, the levels angiotensin-I were increased in both 3 and 6
months old CTSAS190A mice’s serum as 1.3-fold and 1.6-fold,
respectively (Figure 5).
DISCUSSION
CTSA is a lysosomal protein with dual function: protective
and catalytic. CTSA associates with β-galactosidase and α–
neuraminidase forming a multi-enzyme complex to protect these
two enzymes against lysosomal degradation. Independent from
its protective function, CTSA has carboxpeptidase activity at an
acidic pH optimum between pH 4.5 and 5.5 as well as deamidase
and esterase activities at neutral pH which leads the deamination
of peptides (Hiraiwa, 1999).
The carboxyl-terminal end of many physiologically active
peptides is blocked by an amide bond (−CONH2) and these
form of the peptide are less susceptible to degradation. Several
in vitro studies showed that CTSA is involved in activation
or inactivation of these peptides by removing last one or two
amino acid residues (Skidgel and Erdös, 1998). It has been shown
that CTSA hydrolyzes a variety of bioactive peptides including
substances P (Jackman et al., 1990). Report on the different
percentage of relative carboxypeptidase activity against bioactive
peptides such as endothelin I (100%), angiotensin I (9.5%),
bradykinin (6.1%), oxytocin (4%), substances P (3.8%) suggests
that CTSA may play a role in regulation of bioactive peptide
functions (Hiraiwa, 1999).
Previously, it has been demostrated that expression level of
CTSA enzyme has a tissue specific pattern in mice (Galjart et al.,
1990). Although, kidney has the highest, relatively high levels
of expression in brain, liver and lung implicates that CTSA
may have different level of contribution to the hydrolysis of
endogeneous bioactive peptides in different tissues. To elucidate
the in vivo significance of lysosomal CTSA in the regulation of
several endogenous bioactive peptides, we analyzed the levels
of bradykinin, substances P, oxytocin, angiotensin I as well as
endothelin-I in different tissues from knock-in CTSAS190A male
mice at two different age groups.
FIGURE 5 | The levels of bradykinin, substance P, oxytocin, angiotensin I and endothelin-I in the serum of 3-month-old (3M) and 6-month-old (6M)
CathAS190A and WT littermate mice. Data show mean ± SE of measurements in three male mice. Significant levels of Student’s t-tests are shown below the
boxplots. The symbol “ ____ ” indicates significant level of oxytocin and angiotensin I between 3-and 6-month-old CathAS190A mice using the one-way ANOVA
(*p < 0.05 and **p < 0.025).
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Endothelin-I is a peptide composed of twenty-one amino
acids. It is produced mainly in endothelial cells, vascular smooth
muscle cells and a lesser extent by astrocytes, neurons, sertoli
cells and hepatocytes. Endothelin-1 functions as vasoconstrictor
and affects the salt-water equilibrium (Barnes and Turner, 1997).
Endothelin-I is the well-known substrate for CTSA (Jackman
et al., 1992). Previously we have reported that CTSAS190A mice
have an increased level of endothelin-I only in lungs (Seyrantepe
et al., 2008). Our current data showed that not only in lungs
but also in kidney, there is increased level of endothelin-I in
CTSAS190A mice at 6 and 3months old respectively. Although, the
markedly increased endothelin-1-specific immunoreactivity has
been demonstrated in CTSA deficient galactosialidosis patient’s
brain, we did not observe any difference neither in brain nor in
liver from CTSAS190A mice using ELISA (Itoh et al., 2000). We
also speculate that higher expression of other carboxypeptidases
such as Scpep1 may contribute modulating the catabolic
proteolysis of Endothelin-I in these tissues (Pshezhetsky and
Hinek, 2009; Pan et al., 2014).
Bradykinin is a physiologically and pharmacologically active
peptide consists of nine amino acids known to influence
the inflammatory process by affecting various tissue reactions
including vasodilation, permeability of vessels and coagulation
(Maurer et al., 2011). As a neuropeptide, bradykinin in brain
chemotactically attracts glioma cells to blood vessels causing
their migration and significantly changes the physiological
properties of these cells in vivo (Montana and Sontheimer,
2011). We report for the first time that significantly higher
levels of bradykinin in kidney (Figure 1), liver (Figure 2),
lung (Figure 3) and serum (Figure 5) of the CTSAS190A mice
compared to WT mice which indicates CTSA has important
role on inactivation of endogenous bradykinin peptide in vivo.
Interestingly, the comparisons of bradykinin levels in brain from
3 and 6 months old CTSAS190A and their WT siblings measured
by ELISA were not conslusive. Therefore, we suggest that
quantitation of bradykinin in brain using 2D-LC-MS/MS assays
may be uniquely advantageous for elucidating physiological and
biological events.
Substance P consists of eleven amino acids which is released
from both the central and peripheral endings of neurons and
functions as a neurotransmitter which is involved in vasodilation
(reviewed in Harrison and Geppetti, 2001). Substances P plays
role in inflammation through astrocyte and leukocyte activation
at the site of injury (Lorente et al., 2015). A number of
enzymes are required in the metabolism of substances P,
including: neutral endopeptidase (NEP), angiotensin-converting
enzyme (ACE), substance-P-degrading enzyme, cathepsin-D
and cathepsin-E. In our study, among the studied tissues, a
significant accumulation of substances P (5-fold) was observed
in the brain of CTSAS190A mice (Figure 4). This accumulation
in the absence of active CTSA shows that beside other
enzymes CTSA is one of the functional enzymes that are
involved in the metabolism of substances P, especially in mouse
brain.
The role of CTSA in conversion of angiotensin-I to
angiotensin-II suggests that CTSA may be an important player
of the renin-angiotensin system regulating blood pressure and
water balance (Miller et al., 1988). In the classic renin-angiotensin
system enzymatic cascade angiotensinogen is cleaved by renin
and converted to angiotensin I which is further processed by
angiotensin converting enzyme (ACE) to form angiotensin II
(Lavoie et al., 2004). Similar to ACE, CTSA is more likely to
be involved in the in vivo conversion of angiotensin I into
angiotensin II in the human heart (Jackman et al., 2002). In
our results it was showed that elevated levels of angiotensin-
I in kidney (Figure 1) and serum (Figure 5) but not in liver
(Figure 2), lung (Figure 3) and brain (Figure 4) of CTSAS190A
mice. Since Angiotensin-I is an intermediary peptide found
most abundant as inactive form in blood (Lavoie et al.,
2004), it is not surprising that we were able to detect the
increased level of angiotensin I in blood as well as kidney
where the cleavage of angiotensinogen takes place. Our results
clearly implicate that CTSA is important member of renin-
angiotensin system, however, more precise study including
in situ analysis showing the expression level of CTSA and
Angiotensin-I in particular tissues such as renal proximal tubules
is required.
Oxytocin is a mammalian, 9-amino acid cyclic peptide which
is synthesized in biologically active form in the paraventricular
and supra-optic nuclei of the hypothalamus and is released
into the central nervous system as well as the bloodstream
(reviewed in Lee et al., 2009). In addition to brain, oxytocin
and oxytocin receptors are found in several peripheral organs
including heart, kidney, pancreas, breast, thymus, non-pregnant
uterus, bowel and testis of the rat and human (Vargas-Martínez
et al., 2014). Although, the highest densities of oxytocin receptors
were observed in infant rat brain especially in cortex and spinal
cord, low or undetectable numbers of oxytocin receptors were
reported in the adult rat brain. It has been shown that aging
decreases the number of oxytocin binding sites in the other
part of brain (Arsenijevic et al., 1995). Besides its best known
roles in parturition and lactation, oxytocin also plays important
regulatory role in variety of physiological conditions such as
social memory and attachment, sex and maternal behavior,
and human bonding and trust (Gimpl and Fahrenholz, 2001;
Lee et al., 2009). Oxytocin and oxytocin receptor expression is
effected by steroid hormones and gender and it is usually higher
in females (Lee et al., 2009). Therefore, in our research only
male mice were investigated to detect the regulatory function of
CTSA on cleavage off oxytocin peptide in vivo, kidney, liver, lung,
brain and serum. Our results showed that the levels of oxytocin
peptide were significantly higher in kidney (2.3-fold), liver (5.8-
fold), lung (2.4-fold), brain (14.2-fold) and serum (4.1-fold) of
3 months old CTSAS190A mice compared to age matched WT
mice respectively. Our data clearly suggests the role of CTSA
on the cut off oxytocin in different tissues. The decrease in the
oxytocin level in serum and other tissues of 6 months of WT
and CTSAS190A mice as compared to that of 3 months may be
related to the decreased level of oxytocin receptors in the aging
brain.
Over all, our data clearly indicates that CTSA contributes
on the hydrolysis of bioactive peptides in different mouse
tissues including kidney, liver, lung, brain and serum. However,
we expect that further analysis of aging mice (12 months
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old or older) which either can be feed with high-salt diet
or normal diet may provide more insights regarding CTSA
catalytic activity on bioactive peptides and its physiological
role outside of lysosomes. Additionally, high-throughput and
selective 2D-LC-MS/MS bioanalytical methods rather than
sensitive radioimmunoassay (RIA) or ELISA can be applied to
validate the physiological role of this unique enzyme in the
regulation of bioactive peptides as well as determination of its
unknown substrates.
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